A novel cell-permeable LOXL2 inhibitor PAT-1251 potently suppresses biliary liver fibrosis via collagen crosslinking-dependent and -independent mechanisms
{{output}}
Background: LOXL2 promotes fibrosis through extracellular collagen crosslinking and intracellular signaling mechanisms. Here, we studied the mode of action of a novel potent, cell-permeable LOXL2 inhibitor PAT-1251 on hepatic fib... ...
